Summary of patient information
| Patient . | Age . | Race . | Sex . | Transplant . | Days (transplantation to tumor) . | Tumor histology . | Therapy for tumor* . | Time of analysis† . |
|---|---|---|---|---|---|---|---|---|
| P1 | 44 | W | F | Liver | 3110 | Diffuse immunoblastic lymphoma (B cell), EBV+ | XRT, CHOP | Active PTLD |
| P2 | 44 | W | M | Kidney | 2224 | Diffuse large-cell lymphoma (B cell), EBV+ | Withdrawal of immunosuppression | Active PTLD |
| P3 | 48 | W | M | N/A | N/A | Polymorphic B-cell hyperplasia, EBV+ | Withdrawal of immunosuppression | Active PTLD |
| P4 | 48 | W | M | Heart | 2370 | Polymorphic B-cell hyperplasia, EBV+ | CHOP, Etoposide-Ifosfamide | Active PTLD |
| P5 | 49 | W | F | Lung | 190 | Diffuse large-cell lymphoma (B cell), EBV+ | Withdrawal of immunosuppression | Active PTLD |
| P6 | 20 | W | M | Kidney | 1106 | Diffuse immunoblastic lymphoma (B cell), EBV+ | Withdrawal of immunosuppression | Active PTLD |
| P7 | 10 | W | M | Liver | 2920 | Atypical polymorphous lymphoid hyperplasia (B cell), EBV+ | Cytoxan, prednisone | Active PTLD |
| P8 | 34 | W | F | Heart | 2824 | Diffuse large-cell lymphoma (T cell), EBV+ | CHOP, XRT, CVP, EPOCH | Active PTLD |
| P9 | 25 | W | M | Bone marrow | 121 | Diffuse immunoblastic lymphoma (B cell), EBV+ | Donor lymphocyte infusion | Remission |
| P10 | 54 | W | M | Liver | 1992 | Diffuse large-cell lymphoma (B cell), EBV+ | CHOP | Remission |
| P11 | 34 | W | F | Heart | 317 | Diffuse large-cell lymphoma (B cell), EBV+ | ProMACE-CytaBOM | Remission |
| P12 | 61 | W | F | Lung | 106 | Diffuse large-cell lymphoma (B cell), EBV+ | ProMACE-CytaBOM | Remission |
| P13 | 4 | W | M | Liver | 974 | Diffuse small noncleaved cell lymphoma (B cell), EBV+ | Cytoxan, vincristine, ARA-C | Remission |
| P14 | 52 | W | M | Lung | 310 | Diffuse large-cell lymphoma (B cell), EBV+ | CHOP | Remission |
| Patient . | Age . | Race . | Sex . | Transplant . | Days (transplantation to tumor) . | Tumor histology . | Therapy for tumor* . | Time of analysis† . |
|---|---|---|---|---|---|---|---|---|
| P1 | 44 | W | F | Liver | 3110 | Diffuse immunoblastic lymphoma (B cell), EBV+ | XRT, CHOP | Active PTLD |
| P2 | 44 | W | M | Kidney | 2224 | Diffuse large-cell lymphoma (B cell), EBV+ | Withdrawal of immunosuppression | Active PTLD |
| P3 | 48 | W | M | N/A | N/A | Polymorphic B-cell hyperplasia, EBV+ | Withdrawal of immunosuppression | Active PTLD |
| P4 | 48 | W | M | Heart | 2370 | Polymorphic B-cell hyperplasia, EBV+ | CHOP, Etoposide-Ifosfamide | Active PTLD |
| P5 | 49 | W | F | Lung | 190 | Diffuse large-cell lymphoma (B cell), EBV+ | Withdrawal of immunosuppression | Active PTLD |
| P6 | 20 | W | M | Kidney | 1106 | Diffuse immunoblastic lymphoma (B cell), EBV+ | Withdrawal of immunosuppression | Active PTLD |
| P7 | 10 | W | M | Liver | 2920 | Atypical polymorphous lymphoid hyperplasia (B cell), EBV+ | Cytoxan, prednisone | Active PTLD |
| P8 | 34 | W | F | Heart | 2824 | Diffuse large-cell lymphoma (T cell), EBV+ | CHOP, XRT, CVP, EPOCH | Active PTLD |
| P9 | 25 | W | M | Bone marrow | 121 | Diffuse immunoblastic lymphoma (B cell), EBV+ | Donor lymphocyte infusion | Remission |
| P10 | 54 | W | M | Liver | 1992 | Diffuse large-cell lymphoma (B cell), EBV+ | CHOP | Remission |
| P11 | 34 | W | F | Heart | 317 | Diffuse large-cell lymphoma (B cell), EBV+ | ProMACE-CytaBOM | Remission |
| P12 | 61 | W | F | Lung | 106 | Diffuse large-cell lymphoma (B cell), EBV+ | ProMACE-CytaBOM | Remission |
| P13 | 4 | W | M | Liver | 974 | Diffuse small noncleaved cell lymphoma (B cell), EBV+ | Cytoxan, vincristine, ARA-C | Remission |
| P14 | 52 | W | M | Lung | 310 | Diffuse large-cell lymphoma (B cell), EBV+ | CHOP | Remission |
EBV indicates Epstein-Barr virus; N/A, not applicable; PTLD, post-transplantation lymphoproliferative disease; XRT, radiation therapy; CHOP, cyclophosphamide, vincristine, doxorubicin, prednisone; CVP, cyclophosphamide, vincristine, prednisone; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and prednisone; ProMACE-CytaBOM, prednisone, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine, and methotrexate; and cytarabine.
For more information regarding these standard chemotherapy regimens, see Lister et al.41
Active PTLD or PTLD in remission is determined on the basis of whether the patient had evidence of disease by usual clinical evidence (physical examination, computed tomography scan).